Publication Name	World Journal of Pharmacology
Manuscript ID	12854
Country	Italy

Received	2014-07-28 08:46
Peer-Review Started	2014-07-28 19:02
To Make the First Decision	2014-08-14 14:34
Return for Revision	2014-08-18 11:36
Revised	2014-08-29 04:53
Second Decision	2014-09-24 16:12
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2014-09-24 16:24
Articles in Press	2014-09-24 16:24
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2014-11-28 17:55
Publish the Manuscript Online	2014-12-12 11:14

ISSN	2220-3192 (online)
Open Access
Copyright
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Nanoscience & Nanotechnology
Manuscript Type	Review
Article Title	Targeted approaches for HER2 breast cancer therapy: News from nanomedicine?
Manuscript Source	Invited Manuscript
All Author List	Serena Mazzucchelli, Marta Truffi, Luisa Fiandra, Luca Sorrentino and Fabio Corsi
Funding Agency and Grant Number
Corresponding Author	Fabio Corsi, MD, Professor, Department of Biomedical and Clinical Sciences “L. Sacco”, University of Milan, via G. B. Grassi, 74, 20157 Milan, Italy. fabio.corsi@unimi.it
Key Words	Human epidermal growth factor receptor 2; Human epidermal growth factor receptor 2+-breast cancer; Nanomedicine; Nanoparticle; Targeted-therapy
Core Tip	About 30% of human breast cancers are characterized by the overexpression of human epidermal growth factor receptor 2 (HER2) receptor, which determines the deregulation of cell survival and proliferation pathways. The HER2-targeted therapy is the most effective treatment, despite some related limitations, which could be bypassed with the development of nanoparticles for HER2-targeted drug delivery, photothermal ablation or photodynamic therapy. Here, we describe HER2+ breast cancer features and anti-HER2 therapy, and focus on the contribution of nanomedicine in this context, by reporting HER2-targeted nanoparticles under preclinical investigations. Promising results suggest upcoming clinical application of these nano-compounds in the next future.
Publish Date	2014-12-12 11:14
Citation	Mazzucchelli S, Truffi M, Fiandra L, Sorrentino L, Corsi F. Targeted approaches for HER2 breast cancer therapy: News from nanomedicine? World J Pharmacol 2014; 3(4): 72-85
URL	http://www.wjgnet.com/2220-3192/full/v3/i4/72.htm
DOI	http://dx.doi.org/10.5497/wjp.v3.i4.72

Full Article (PDF)	WJP-3-72.pdf
Full Article (Word)	WJP-3-72.doc
Manuscript File	12854-Review.docx
Answering Reviewers	12854-Answering reviewers.pdf
Copyright License Agreement	12854-Copyright assignment.pdf
Peer-review Report	12854-Peer review(s).pdf
Scientific Misconduct Check	12854-CrossCheck.jpg
Scientific Editor Work List	12854-Scientific editor work list.pdf